Asterias Biotherapeutics Inc (NYSE:AST) received a $12.00 price objective from investment analysts at HC Wainwright in a research note issued to investors on Thursday. The firm presently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s price target indicates a potential upside of 263.64% from the company’s previous close.

Separately, Zacks Investment Research upgraded shares of Asterias Biotherapeutics from a “hold” rating to a “buy” rating and set a $4.00 price target on the stock in a research note on Monday, July 17th.

Shares of Asterias Biotherapeutics (AST) opened at 3.30 on Thursday. Asterias Biotherapeutics has a 12-month low of $2.54 and a 12-month high of $5.80. The stock’s 50 day moving average is $3.49 and its 200-day moving average is $3.46. The stock’s market cap is $162.57 million.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by Watch List News and is owned by of Watch List News. If you are accessing this news story on another website, it was copied illegally and republished in violation of US and international trademark and copyright legislation. The original version of this news story can be accessed at

Asterias Biotherapeutics Company Profile

Asterias Biotherapeutics, Inc is a biotechnology company. The Company is engaged in developing and commercializing therapies in the fields of cell therapy and regenerative medicine. The Company has over two technology platforms. The first is an immunotherapy platform to teach cancer patients’ immune systems to attack their tumors.

Receive News & Ratings for Asterias Biotherapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Asterias Biotherapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.